alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 376–400 of 903 studies (page 16 of 37) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 903 studies tagged small — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Volumetric Changes in Cerebellar Transverse Zones: Age and Sex Effects in Health and Neurological Disorders

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Human Brain Mapping 2025-04-15

Cerebellar volumetric changes are intricately linked to aging, with distinct patterns across its transverse zones, the functional subdivisions characterized by unique cytoarchitectural and connectivity profiles. 5 key findings →

Participants: 45,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of multimorbidity and disease clusters with neuroimaging and cognitive outcomes in UK Biobank

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-05-26

A total of 43,160 participants were included (mean [standard deviation] age, 64.2 [7.7] years, 53.1 % female). 5 key findings →

Design: cross-sectional Participants: 43,160 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Diabetes Obesity and Metabolism 2025-04-02

MASLD was significantly associated with smaller volumes of total grey matter and subcortical grey matter (p < 0.05) and reduced Alzheimer's disease (AD)-signature cortical thickness (multivariable-adjusted β = -0.04; 95% confidence interval [CI]: -0.07, -0.01). 4 key findings →

Design: cross-sectional Participants: 29,195 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

White matter hyperintensity burden predicts domain-specific cognitive decline across the Alzheimer’s disease continuum

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Scientific Reports 2025-11-25

White matter hyperintensity (WMH), indicative of cerebral small vessel disease, has emerged as a potential biomarker for cognitive decline in Alzheimer's disease (AD). 2 key findings →

Design: cross-sectional Participants: 158 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The role of inflammation in cerebral small vessel disease and vascular cognitive impairment, and therapeutic implications

✓ Peer-reviewed alzhub usefulness score 51 out of 100. International Journal of Stroke 2026-06-08

Considerable data support the presence of both systemic and CNS inflammation in SVD and VCID. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2006-05-01

The NBV significantly correlated with all clinical scores (Rankin, NIH Stroke Scale, Barthel, structured interview for the diagnosis of Alzheimer dementia and multi-infarct dementia, Mattis dementia rating scale) at both time points independently of age and sex. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2005-01-01

Blood pressure and indicators of small-vessel disease in the brain may be associated with atrophy of structures affected by Alzheimer pathology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Heterogeneous histopathology of cortical microbleeds in cerebral amyloid angiopathy

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2016-02-03

This study provides evidence for heterogeneous pathologic substrates and possibly different pathophysiologic mechanisms underlying MRI-observed cortical microbleeds in the context of advanced CAA and Alzheimer disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Molecular psychiatry 2014-08-05

Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Circulation. Cardiovascular quality and outcomes 2016-02-01

Hypertensive pregnancy disorders are associated with worse performance on tests of processing speed and smaller brain volumes decades later. 4 key findings →

Participants: 1,279 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropathology of White Matter Lesions, Blood-Brain Barrier Dysfunction, and Dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Stroke 2017-08-30

Our data suggest that some degree of blood-brain barrier dysfunction is common in older people and that this may be related to clinical dementia risk, additional to standard MRI biomarkers. 5 key findings →

Participants: 126 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. The Journal of clinical investigation 2010-01-11

Cerebral ischemic small vessel disease (SVD) is the leading cause of vascular dementia and a major contributor to stroke in humans. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

8 of the 902 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed